Article info

Download PDFPDF
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice

Authors

  1. Correspondence to Dr Orhan Aktas, Department of Neurology, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf D-40225, Germany; orhan.aktas{at}uni-duesseldorf.de
View Full Text

Citation

Aktas O
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice

Publication history

  • Received October 21, 2014
  • Accepted October 22, 2014
  • First published November 10, 2014.
Online issue publication 
February 12, 2015

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.